About us

Energenesis's Novel Diabetic Foot Ulcer Gel Wins Excellence Award in Innovation Technology at 2024 Taipei Biotech Awards

Australian Patent Granted for "METHODS FORTREATING DIABETIC ULCER" Following PCT National Phase Entry

Thank you for meeting us at 2024 BIO Europe Spring

We welcome you to visit us at 2024 EWMA Conference

Meet us at 2024 BIO International Convention

Orphan Drug Designation Granted to ENERGI-F703EB by the Committee for Orphan Medicinal Products(COMP) of the European Medicines Agency (EMA)

Energenesis Biomedical has jointly signed a technical service contract with National Taiwan University and Yen Ching Ling Industrial Development Found

Our invention patent for "Compound Activating AMPK and its Use" for the treatment of prediabetes and type 2 diabetes has been approved in Ca

ENERGI-F703 diabetic foot ulcer topical gel has received approval from the Taiwan Food and Drug Administration (TFDA) to initiate Phase III clinical t

Announcement: Energenesis Biomedical has signed a Memorandum of Understanding (MOU) with Healiva SA, a company based in Switzerland, to establish a